Literature DB >> 12208321

Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

Ognjen Culić1, Vesna Eraković, Ivana Cepelak, Karmela Barisić, Karmen Brajsa, Zeljko Ferencić, Ruzica Galović, Ines Glojnarić, Zoran Manojlović, Vesna Munić, Renata Novak-Mircetić, Verica Pavicić-Beljak, Mirna Sucić, Marija Veljaca, Tihana Zanić-Grubisić, Michael J Parnham.   

Abstract

Effects on human neutrophils and circulating inflammatory mediators were studied in 12 volunteers who received azithromycin (500 mg/day, p.o.) for 3 days. Blood was taken 1 h before treatment, 2.5, 24 h and 28 days after the last dose. An initial neutrophil degranulating effect of azithromycin was reflected in rapid decreases in azurophilic granule enzyme activities in cells and corresponding increases in serum. The oxidative response to a particulate stimulus was also acutely enhanced. These actions were associated with high plasma and neutrophil drug concentrations. A continuous fall in chemokine and interleukin-6 serum concentrations, within the non-pathological range, accompanied a delayed down-regulation of the oxidative burst and an increase in apoptosis of neutrophils up to 28 days after the last azithromycin dose. Neutrophils isolated from blood at this time point still contained detectable drug concentrations. Acute neutrophil stimulation could facilitate antibacterial effects of azithromycin, while delayed, potentially anti-inflammatory activity may curtail deleterious inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208321     DOI: 10.1016/s0014-2999(02)02042-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  61 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

2.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

3.  Risk of cardiovascular effects with azithromycin.

Authors:  Ramachandran Kumaresan; Subish Palaian; Santosh Thapa; Pathiyil Ravi Shankar
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 4.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

5.  Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.

Authors:  Bryan Z Wilson; Antonio Anzueto; Marcos I Restrepo; Mary Jo V Pugh; Eric M Mortensen
Journal:  Crit Care Med       Date:  2012-08       Impact factor: 7.598

6.  Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells.

Authors:  Cristina Cigana; Baroukh Maurice Assael; Paola Melotti
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

Review 7.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

8.  Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.

Authors:  David P Nichols; Silvia Caceres; Lindsay Caverly; Cori Fratelli; Sun Ho Kim; Ken Malcolm; Katie R Poch; Milene Saavedra; George Solomon; Jennifer Taylor-Cousar; Samuel Moskowitz; Jerry A Nick
Journal:  J Surg Res       Date:  2013-02-24       Impact factor: 2.192

9.  Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Authors:  Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.